磷虾含有粘合的脂质体作为有效的nanovehicle，以改善DSS诱导的结肠炎的炎症反应

Jin-hee Kim

sub_abstract_label“>背景： packy> phophoptrandyylcholine and pcipision-pcication and pcication and pc acty and pc acty and pc acto-pc acte and pc）治疗炎症性肠病（IBD）的治疗分子。

目的： 基于纳米颗粒的IBD治疗潜力，We herein sought to develop Omega-3-incorporated PC nanoparticles (liposomes) as an orally administrable vehicle for treating IBD.

Methods: Liposomes prepared with or without Omega-3 incorporation were compared in terms of colloidal stability and anitiinflammatory效果。

结果： 掺入游离omega-3（α-氯苯甲酸，eicosapentaenoic，eicosapentaenoic或docosahecahecahexaenoic acigy）在脂质体中诱导的时间依赖性依赖性的膜融合量的散布在粒子中均增加了。相比之下，将磷虾油掺入脂质体（KO脂质体）中不会诱导融合，并且储存过程中的粒径保持在含量<250 nm。 KO脂质体在模拟的胃肠道条件下还保持了胶体稳定性，并表现出诱使IBD药物Budesonide（BDS）的高能力。 KO脂质体极大地抑制了脂多糖诱导的PR在培养的巨噬细胞中促炎性细胞因子的刺激以及在肠道屏障模型中完全恢复的炎症障碍膜屏障功能的刺激。 In mice subjected to dextran sulfate sodium-induced colitis, oral administration of BDS-entrapped KO liposomes suppressed tumor necrosis factor-α production (by 84.1%), interleukin-6 production (by 35.3%), and the systemic level of endotoxin (by 96.8%), and slightly reduced the macroscopic signs of the disease.

Conclusion: Taken together, KO liposomes may have great potential as a nanovehicle for oral delivery of IBD drugs.